845829-94-9

Basic information

• Product Name: 2-Bromo-6-fluoroanisole
• Synonyms: 2-BROMO-6-FLUOROANISOLE;1-BROMO-3-FLUORO-2-METHOXY-BENZENE;Benzene, 1- bromo- 3- fluoro- 2- methoxy-
• CAS NO: 845829-94-9
• Molecular Formula: C₇H₆BrFO
• Molecular Weight: 205.02
• EINECS: 679-553-0
• Product Categories: Benzene series;Benzenes
• Mol File: 845829-94-9.mol

Chemical Properties

• Boiling Point: 208.587 °C at 760 mmHg
• Flash Point: 94.379 °C
• Appearance: /
• Density: 1.532 g/cm³
• Vapor Pressure: 0.306mmHg at 25°C
• Refractive Index: 1.518
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-Bromo-6-fluoroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Bromo-6-fluoroanisole(845829-94-9)
• EPA Substance Registry System: 2-Bromo-6-fluoroanisole(845829-94-9)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 845829-94-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-6-fluoroanisole is used as a reactant in the preparation of quinazoline compounds, which serve as c-jun N-terminal kinase (JNK) inhibitors. These inhibitors are of interest due to their potential therapeutic applications, particularly in the treatment of neurological disorders and conditions that involve the JNK signaling pathway. The good brain penetration of these inhibitors is a significant advantage for their use in central nervous system-related treatments.

InChI:InChI=1/C7H6BrFO/c1-10-7-5(8)3-2-4-6(7)9/h2-4H,1H3

Upstream product

• 437-83-2 3-fluoro-2-methoxyaniline 
• 367-12-4 2-fluorophenol 
• 875664-44-1 C₇H₇BrFNO 
• 374633-24-6 1-bromo-2,3-difluoro-5-nitrobenzene 
• 369-34-6 3,4-difluoronitrobenzene 
• 2040-89-3 2-bromo-6-fluorophenol 
• 74-88-4 methyl iodide 
• 484-94-6 1-fluoro-2-methoxy-3-nitrobenzene 
• 1526-17-6 2-fluoro-6-nitrophenol 

Downstream Products

• 194804-92-7 4-bromo-2-fluoro-3-methoxybenzoic acid 
• 194804-99-4 ethyl 3-(4-bromo-2-fluoro-3-methoxyphenyl)-3-oxopropionate 
• 91659-03-9 4-bromo-2-fluoro-3-methoxybenzoic acid 
• 1403598-29-7 tert-butyl 4-(3-fluoro-2-methoxyphenyl)-3,6-dihydropyridine-1(2H)-carboxylate 
• 1403598-30-0 4-(3-fluoro-2-methoxyphenyl)piperidine hydrochloride 
• 1403598-31-1 2-bromo-4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]pyridine-3-carbonitrile 
• 1403598-32-2 4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]-2-hydrazinopyridine-3-carbonitrile 
• 1403598-33-3 N'-{3-cyano-4-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]-pyridin-2-yl}-3,3,3-trifluoropropanehydrazide 
• 1254977-71-3 7-[4-(3-fluoro-2-methoxyphenyl)piperidin-1-yl]-3-(2,2,2-trifluoroethyl)[1,2,4]triazolo[4,3-a]pyridine-8-carbonitrile 
• 1376334-45-0 8-chloro-3-(cyclopropylmethyl)-7-[4-(3-fluoro-2-methoxyphenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine 
• 1376334-50-7 3-(cyclopropylmethyl)-7-[4-(3-fluoro-2-methoxyphenyl)-1-piperidinyl]-8-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyridine 
• 1376335-27-1 4-(3-fluoro-2-methoxy-phenyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 1426073-33-7 4-bromo-2-fluoro-3-methoxybenzonitrile 

Relevant articles and documents

Preparation method of 2-bromo-6-fluoroanisole

The invention discloses a preparation method of 2-bromine-6-fluoroanisole, the preparation method comprises the following specific steps: (1) carrying out electrophilic substitution reaction on 3, 4-difluoronitrobenzene and bromosuccinimide to generate a compound III; (2) reacting the compound III with sodium methoxide to generate a compound IV; (3) reducing the compound IV by sodium hydrosulfite to generate a compound V; (4) performing diazotization deamination on the compound V to generate a compound I; the obtained product is 2-bromo-6-fluoroanisole. The preparation method is higher in yield.

COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND F1BROTIC DISEASE

Provided herein are methods and compositions for treating cancers, inflammatory diseases, rasopathies, and fibrotic disease involving aberrant Ras superfamily signaling through the binding of compounds to the GTP binding domain of Ras superfamily proteins including, in certain cases, K-Ras and mutants thereof, and a method for assaying such compositions.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Phenyl acetate derivatives, fluorine-substituted on the phenyl group, as rapid recovery hypnotic agents with reflex depression

We report the synthesis of novel, potentially hypnotic fluorine-substituted phenyl acetate derivatives. We describe the structure-activity relationship that led us to the promising derivative: ethyl 2-(4-(2-(diethylamino)-2-oxoethoxy)-5-ethoxy-2-fluorophenyl) acetate (55). The unique pharmacological features of compound 55 are its relatively high affinity for the GABAA receptor, together with a unique affinity for the NMDA receptor, different to propanidid and AZD3043. In animal models, compound 55 showed stronger hypnotic potency and longer duration of LORR than propanidid and AZD3043, but also maintained a rapid recovery time to walking and behavioral recovery. In particular, compound 55 displayed reflex depression during infusion.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula(I) or a pharmaceutically acceptable salt thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: Effects of structural modifications at the 6-, 7-, and 8-positions

We describe the biological evaluation of isothiazoloquinolones (ITQs) having structural modifications at the 6-, 7-, and 8-positions. Addition of a methoxy substituent to C-8 effected an increase in antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and a decrease in cytotoxic activity against Hep2 cells. Removal of fluorine from C-6 or replacement of the C-8 carbon with a nitrogen compromised anti-MRSA activity. When the groups attached at C-7 were compared, the anti-MRSA activity decreased in the order 6-isoquinolinyl > 4-pyridinyl > 5-dihydroisoindolyl > 6-tetrahydroisoquinolinyl. The compound with the most desirable in vitro biological profile was 9-cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpyridin-4-yl) -9H-isothiazolo[5,4-b]quinoline-3,4-dione (7g). This ITQ demonstrated (i) strong in vitro anti-MRSA activity (MIC90 = 0.5 μg/mL), (ii) strong inhibitory activities against S. aureus DNA gyrase and topoisomerase IV, with weak activity against human topoisomerase II, (iii) weak cytotoxic activities against three cell lines, and (iv) efficacy in an in vivo murine thigh model of infection employing MRSA.

NEW ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

The invention provides certain compounds and salts of Formula I and Formula II:which possess antimicrobial activity. The invention also provides novel synthetic intermediatesuseful in making compounds of Formula I and Formula II. The variables A1, R2, R3, R5, R6, R7, A8, and Rg are defined herein. Certain compounds of Formula I and Formula II disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula I or Formula II and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula I or Formula II as the only active agent or may contain a combination of a compound of Formula I or Formula II and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

ISOTHIAZOLOQUINOLONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

The invention provides compounds and salts of Formula (I) and Formula (II): which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables A1, R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.